Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
Close
  • Menu
  • Setting

BFH772

Catalog No.
B6199
VEGFR2 inhibitor
Grouped product items
Size Price Stock Qty
1mg
Special Price $37.35 Regular Price $83.00
In stock
5mg
Special Price $67.05 Regular Price $149.00
In stock
10mg
Special Price $111.60 Regular Price $248.00
In stock
25mg
Special Price $223.65 Regular Price $497.00
In stock
50mg
Special Price $334.80 Regular Price $744.00
In stock
100mg
Special Price $632.70 Regular Price $1,406.00
Ship with 10-15 days
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: sales@apexbt.com

Worldwide Distributors

No Related Posts

Background

IC50: 3 nM

BFH772 is a VEGFR2 inhibitor.

The VEGF family including VEGF-A, VEGF-B, VEGF-C, VEGF-D, and PlGF signals through VEGFR1, VEGFR2, and VEGFR3 cell surface tyrosine kinase receptors that are located on the host vascular endothelium, lymphatic, and hematopoietic systems.

In vitro: BFH772 was highly effective at targeting VEGFR2 kinase, however, lost 500-fold potency on FLK-1, FLT-1, and FLT-4. BFH772 also targeted B-RAF, RET, and TIE-2, albeit with at least 40-fold lower potency. BFH772 inhibited the ligand induced autophosphorylation of RET, PDGFR, and KIT kinases. BFH772 was selective against the kinases of EGFR, ERBB2, INS-R, and IGF-1R and against the cytoplasmic BCR-ABL kinase [1].

In vivo: The dose response curves of BFH772 at 0.3, 1, and 3 mg/kg showed that even at the lowest concentrations, this naphthalene-1-carboxamide inhibited VEGF induced tissue weight and TIE-2 levels but only reached statistical significance at 1 mg/kg and above. Moreover, BFH772 at 3 mg/kg orally dosed once per day could potently inhibit melanoma growth (54-90% for primary tumor and 71-96% for metastasis tumor) when compared with control ratios [1].

Clinical trial: A proof of concept study to evaluate the safety, tolerability, and efficacy of 12 week administration of BFH772 ointment in rosacea patients has completed, but no result data are released [2].

References:
[1] Bold G, et al.  A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis. J Med Chem. 2016 Jan 14;59(1):132-46.
[2] http://adisinsight. springer.com/trials/700244037

Chemical Properties

StorageStore at -20°C
M.Wt439.39
Cas No.890128-81-1
FormulaC23H16F3N3O3
Solubility≥53.4 mg/mL in DMSO; ≥15.33 mg/mL in EtOH; insoluble in H2O
Chemical Name6-((6-(hydroxymethyl)pyrimidin-4-yl)oxy)-N-(3-(trifluoromethyl)phenyl)-1-naphthamide
SDFDownload SDF
Canonical SMILESO=C(C1=C2C=CC(OC3=NC=NC(CO)=C3)=CC2=CC=C1)NC4=CC=CC(C(F)(F)F)=C4
Shipping ConditionSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips We do not recommend long-term storage for the solution, please use it up soon.

Quality Control